Genetically engineered herpes virus for the treatment of cardiovascular disease
US6846670B2 · kind B2 · utility
19Cited by
16References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 28, 2001 |
| Grant date | Jan 25, 2005 |
| Priority date | — |
| Expiry date | Dec 25, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16661
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one addition pharmacological agent or surgical procedure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.